Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$30.30
+1.40 (+4.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $28.2M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
11.6x
↓EV/EBITDA
8.0x
↓ROE
11.5%
↑Gross Margin
21.1%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.0%
FCF CAGR
-0.3%
FCF margin
6.7%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.06B · net income $96.3M · FCF $71.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.06B | $1.06B | $690.0M | $753.3M | $712.5M |
| Net Income | $96.3M | $96.3M | $-53.5M | $15.3M | $51.6M |
| EBITDA | $175.9M | $175.9M | $20.7M | $88.2M | $125.5M |
| EPS | — | — | -1.46 | 0.42 | 1.55 |
| Gross Margin | 21.1% | 21.1% | 10.8% | 20.3% | 28.9% |
| Operating Margin | 10.5% | 10.5% | -7.2% | 3.4% | 9.5% |
| Net Margin | 9.1% | 9.1% | -7.8% | 2.0% | 7.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.64 | 0.63 | 0.79 |
| Current Ratio | 1.81 | 1.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $71.3M | $71.3M | $28.2M | $256000.00 | $71.8M |
| Returns | |||||
| ROE | 11.5% | 11.5% | -7.4% | 2.0% | 7.8% |
| Valuation | |||||
| P/E | 11.61 | 11.61 | — | 83.81 | — |
| EV/EBITDA | 7.97 | 7.97 | 62.42 | 18.52 | — |
| P/B | 1.35 | 1.35 | 1.29 | 1.63 | — |
| Growth & Yield | |||||
| Revenue Growth | 53.1% | 53.1% | -8.4% | 5.7% | — |
| EPS Growth | — | — | -447.6% | -72.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.46 → n/d
Residual
+43.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.